We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Gilead Sciences Inc (GILD) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$70.93 after a previous close of US$71.61. During the day the price has varied from a low of USD70.34 to a high of USD71.91. The latest price was USD70.96 (25 minute delay). Gilead Sciences is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| Open | US$70.93 |
|---|---|
| High | US$71.91 |
| Low | US$70.34 |
| Close | US$70.96 |
| Previous close | US$71.61 |
| Change | US$-0.65 |
| Change % | -0.9077% |
| Volume | 8,706,094 |
| 52-week range | US$54.7745 - US$72.608 |
|---|---|
| 50-day moving average | US$70.95 |
| 200-day moving average | US$67.6207 |
| Target price | US$75.99 |
| PE ratio | 17.53 |
| Dividend yield | US$2.78 (3.9%) |
| Earnings per share (TTM) | US$4.085 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $70.96
| 1 week (2021-09-14) | 0.72% |
|---|---|
| 1 month (2021-08-20) | -2.04% |
| 3 months (2021-06-21) | 5.36% |
| 6 months (2021-03-19) | 10.08% |
| 1 year (2020-09-18) | 9.09% |
|---|---|
| 2 years (2019-09-20) | 6.84% |
| 3 years (2018-09-20) | -5.17% |
| 5 years (2016-09-20) | -13.23% |
Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Gilead Sciences shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5565. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$14.2 billion (£10.4 billion).
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$26.6 billion |
|---|---|
| Operating margin TTM | 46.82% |
| Gross profit TTM | US$21 billion |
| Return on assets TTM | 12.58% |
| Return on equity TTM | 27.14% |
| Profit margin | 19.38% |
| Book value | 15.712 |
| Market capitalisation | US$89.8 billion |
TTM: trailing 12 months
There are currently 22.5 million Gilead Sciences shares held short by investors – that's known as Gilead Sciences's "short interest". This figure is 12.7% down from 25.7 million last month.
There are a few different ways that this level of interest in shorting Gilead Sciences shares can be evaluated.
Gilead Sciences's "short interest ratio" (SIR) is the quantity of Gilead Sciences shares currently shorted divided by the average quantity of Gilead Sciences shares traded daily (recently around 6.0 million). Gilead Sciences's SIR currently stands at 3.74. In other words for every 100,000 Gilead Sciences shares traded daily on the market, roughly 3740 shares are currently held short.
However Gilead Sciences's short interest can also be evaluated against the total number of Gilead Sciences shares, or, against the total number of tradable Gilead Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gilead Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Gilead Sciences shares in existence, roughly 20 shares are currently held short) or 0.0179% of the tradable shares (for every 100,000 tradable Gilead Sciences shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gilead Sciences.
Find out more about how you can short Gilead Sciences stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Gilead Sciences Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 22.15 |
|---|---|
| Total ESG percentile | 30.98 |
| Environmental score | 0.53 |
| Environmental score percentile | 2 |
| Social score | 12.97 |
| Social score percentile | 2 |
| Governance score | 7.65 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Dividend payout ratio: 34.06% of net profits
Recently Gilead Sciences has paid out, on average, around 34.06% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.98% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 3.98% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.78 per share.
While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.
Gilead Sciences's most recent dividend payout was on 28 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 13 September 2021 (the "ex-dividend date").
Gilead Sciences's shares were split on a 2:1 basis on 27 January 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as US$54.7745 up to US$72.608. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.4132. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Shares in the telecoms operator have jumped nearly 40% over the last 12 months.
This guide will show you step-by-step instructions on how to buy the IRON Titanium Token (TITAN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Wabi (WABI) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Cindicator (CND) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the MonaCoin (MONA) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Bluzelle (BLZ) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Whitecoin (XWC) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Storj (STORJ) token as well as a list of exchanges you can trade it on.
Despite the good news, Qantas shares closed flat following the announcement, but that could change in the coming weeks.
Shares in the lithium producer are up five-fold over the last 12 months.
